Literature DB >> 16968694

Ras triggers ataxia-telangiectasia-mutated and Rad-3-related activation and apoptosis through sustained mitogenic signaling.

Aphrothiti J Fikaris1, Aurélia E Lewis, Adili Abulaiti, Oxana M Tsygankova, Judy L Meinkoth.   

Abstract

Genetic evidence indicates that Ras plays a critical role in the initiation and progression of human thyroid tumors. Paradoxically, acute expression of activated Ras in normal rat thyroid cells induced deregulated cell cycle progression and apoptosis. We investigated whether cell cycle progression was required for Ras-stimulated apoptosis. Ras increased CDK-2 activity following its introduction into quiescent cells. Apoptotic cells exhibited a sustained increase in CDK-2 activity, accompanied by the loss of CDK-2-associated p27. Blockade of Ras-induced CDK-2 activity and S phase entry via overexpression of p27 inhibited apoptosis. Inactivation of the retinoblastoma protein in quiescent cells through expression of HPV-E7 stimulated cell cycle progression and apoptosis, indicating that deregulated cell cycle progression is sufficient to induce apoptosis. Ras failed to induce G1 phase growth arrest in normal rat thyroid cells. Rather, Ras-expressing thyroid cells progressed into S and G2 phases and evoked a checkpoint response characterized by the activation of ATR. Ras-stimulated ATR activity, as evidenced by Chk1 and p53 phosphorylation, was blocked by p27, suggesting that cell cycle progression triggers checkpoint activation, likely as a consequence of replication stress. These data reveal that Ras is capable of inducing a DNA damage response with characteristics similar to those reported in precancerous lesions. Our findings also suggest that the frequent mutational activation of Ras in thyroid tumors reflects the ability of Ras-expressing cells to bypass checkpoints and evade apoptosis rather than to simply increase proliferative potential.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16968694     DOI: 10.1074/jbc.M606737200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.

Authors:  Oren Gilad; Barzin Y Nabet; Ryan L Ragland; David W Schoppy; Kevin D Smith; Amy C Durham; Eric J Brown
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

2.  Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

Authors:  Xin-Yan Pei; Yun Dai; Leena E Youssefian; Shuang Chen; Wesley W Bodie; Yukie Takabatake; Jessica Felthousen; Jorge A Almenara; Lora B Kramer; Paul Dent; Steven Grant
Journal:  Blood       Date:  2011-09-12       Impact factor: 22.113

3.  AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer.

Authors:  Daniela Welcker; Manaswita Jain; Safiya Khurshid; Mladen Jokić; Martin Höhne; Anna Schmitt; Peter Frommolt; Carien M Niessen; Judith Spiro; Thorsten Persigehl; Maike Wittersheim; Reinhard Büttner; Maurizio Fanciulli; Bernhard Schermer; Hans Christian Reinhardt; Thomas Benzing; Katja Höpker
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

4.  Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

Authors:  Khanh Do; Deborah Wilsker; Jiuping Ji; Jennifer Zlott; Tomoko Freshwater; Robert J Kinders; Jerry Collins; Alice P Chen; James H Doroshow; Shivaani Kummar
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

5.  Downregulation of Rap1GAP contributes to Ras transformation.

Authors:  Oxana M Tsygankova; Gregory V Prendergast; Kanchan Puttaswamy; Yan Wang; Michael D Feldman; Hongbin Wang; Marcia S Brose; Judy L Meinkoth
Journal:  Mol Cell Biol       Date:  2007-07-23       Impact factor: 4.272

6.  Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.

Authors:  Andreas Neubauer; Kati Maharry; Krzysztof Mrózek; Christian Thiede; Guido Marcucci; Peter Paschka; Robert J Mayer; Richard A Larson; Edison T Liu; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544

Review 7.  Death pathways triggered by activated Ras in cancer cells.

Authors:  Jean H Overmeyer; William A Maltese
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

8.  The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine.

Authors:  Ebtesam I Ahmad; Heba H Gawish; Nashwa Ma Al Azizi; Ashraf M Elhefni
Journal:  Onco Targets Ther       Date:  2011-07-15       Impact factor: 4.147

9.  Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation.

Authors:  Y Aylon; N Yabuta; H Besserglick; Y Buganim; V Rotter; H Nojima; M Oren
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

10.  Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.

Authors:  Mona Meyer; Daniela Rübsamen; Robert Slany; Thomas Illmer; Kathleen Stabla; Petra Roth; Thorsten Stiewe; Martin Eilers; Andreas Neubauer
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.